Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - rituximabum - concentrato per soluzione per infusione - rituximabum 100 mg, natrii citras dihydricus, polysorbatum 80, natrii chloridum, acidum hydrochloridum aut natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 52.6 mg. - non-hodgkin-lymphom, rheumatoide artrite, anca-assoziierte vasculite - biotechnologika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - rituximabum - concentrato per soluzione per infusione - rituximabum 500 mg, natrii citras dihydricus, polysorbatum 80, natrii chloridum, acidum hydrochloridum aut natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 50 ml corresp. natrium 263.2 mg. - non-hodgkin-lymphom, rheumatoide artrite, anca-assoziierte vasculite - biotechnologika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - canakinumabum - polvere per soluzione iniettabile - preparazione cryodesiccata: canakinumabum 150 mg, zucchero, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, per il vetro. - cryopyrin associati a sindromi periodiche (cap), come di muckle-wells-sindrome (mws), del familiare autoinflammatorischen freddo-sindrome (facs) / familiare kälteurtikaria (fcu) e multisystemischen malattia infiammatoria con inizio in età neonatale (nomid)/cronica infantile neuro-dermo-artikulären sindrome (cinca).; fattore di necrosi tumorale-recettore associato periodico sindrome (trap).; hyperimmunglobulin-d-sindrome (hids) / mevalonatkinasedefizienz (mkd).; la febbre mediterranea familiare (fmf).; siste - biotechnologika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - canakinumabum - polvere per soluzione iniettabile (injektionskit) - preparazione cryodesiccata: canakinumabum 150 mg, zucchero, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, per il vetro. rilascio: acqua iniectabilia 5 ml di vetro. - cryopyrin associati a sindromi periodiche (cap), come di muckle-wells-sindrome (mws), del familiare autoinflammatorischen freddo-sindrome (facs) / familiare kälteurtikaria (fcu) e multisystemischen malattia infiammatoria con inizio in età neonatale (nomid)/cronica infantile neuro-dermo-artikulären sindrome (cinca).; fattore di necrosi tumorale-recettore associato periodico sindrome (trap).; hyperimmunglobulin-d-sindrome (hids) / mevalonatkinasedefizienz (mkd).; la febbre mediterranea familiare (fmf).; siste - biotechnologika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - canakinumabum - soluzione iniettabile - canakinumabum 150 mg, mannitolum, histidinum aut histidini hydrochloridum monohydricum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - cryopyrin-assoziierte periodische syndrome (caps) wie des muckle-wells-syndroms (mws), des familiären autoinflammatorischen kälte-syndroms (facs) / der familiären kälteurtikaria (fcu) und der multisystemischen entzündlichen erkrankung mit beginn im neugeborenenalter (nomid)/des chronischen infantilen neuro-dermo-artikulären syndroms (cinca).; tumornekrosefaktor-rezeptor-assoziiertes periodisches syndrom (traps).; hyperimmunglobulin-d-syndrom (hids) / mevalonatkinasedefizienz (mkd).; familiäres mittelmeerfieber (fmf).; systemische juvenile idiopathische arthritis (sjia).; adultes still-syndrom. - biotechnologika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - rituximabum - soluzione per infusione - rituximabum 100 mg, natrii chloridum, trinatrii citras dihydricus, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 52.6 mg. - linfoma non-hodgkin, artrite reumatoide, vasculite associata con anca - biotechnologika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

iqone healthcare switzerland sa - rituximabum - soluzione per infusione - rituximabum 500 mg, natrii chloridum, trinatrii citras dihydricus, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 50 ml corresp. natrium 263.2 mg. - linfoma non-hodgkin, artrite reumatoide, vasculite associata con anca - biotechnologika

European Union - Italian - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrite, reumatoide - immunosoppressori - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

European Union - Italian - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriasi - immunosoppressori - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.